A Phase 1 interventional study of HS-10504; midazolam in NSCLC, sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Jiangsu Hansoh Pharmaceutical Co., Ltd. (part of Hansoh Pharmaceutical Group Company Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is an open-label, fixed-sequence Phase I clinical trial to evaluate the effect of HS-10504 on the pharmacokinetics of midazolam (CYP3A4 substrate) in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression during or after treatment with EGFR-TKIs.
This study consists of two stages: Stage 1 (DDI evaluation period, C0D1 to C2D21) and Stage 2 (drug donation period, from C3D1 onward). Each cycle contains 21 days, except for Cycle 0.
Stage 1 (DDI evaluation period, C0D1 to C2D21): Enrolled participants receive a single oral dose of midazolam oral solution 1 mg (2 mg/mL, 0.5 mL) on C0D1 and C2D20, respectively; and receive HS-10504 tablets 400 mg (100 mg/tablet, 4 tablets) once daily from C1D1 to C2D21.
Stage 2 (drug donation period, from C3D1 onward): After completing Stage 1, participants may decide, based on the investigator's judgment and their own willingness, whether to enter Stage 2 (the extended drug donation period, which is optional and not mandatory). This stage continues until the participant voluntarily requests discontinuation, is lost to follow-up, experiences disease progression, develops intolerable toxicity, is judged by the investigator to no longer derive benefit from the treatment, or the drug has been approved for marketing, whichever occurs first.
Jiangsu Hansoh Pharmaceutical Co., Ltd. is the lead sponsor of 138 studies on the registry; 72 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has received or is currently receiving the following treatments:
Meets any of the following cardiac criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug-drug interaction Arm
Drug: HS-10504; midazolam
HS-10504:Participants receive HS-10504 tablets 400 mg (100 mg/tablet, 4 tablets) once daily Midazolam:Participants receive a single oral dose of midazolam oral solution 1 mg (2 mg/mL, 0.5 mL) on C0D1 and C2D20, respectively。
Evaluation of PK parameters of Midazolam: Cmax
To evaluate the Cmax of Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of Midazolam: AUC0-t
To evaluate the AUC0-t of Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of Midazolam: AUC0-∞
To evaluate the AUC0-∞ of Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of Midazolam: Tmax
To evaluate the Tmax of Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of Midazolam: t1/2z
To evaluate the t1/2z of Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of Midazolam: λz
To evaluate the λz of Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of Midazolam: CLz/F
To evaluate the CLz/F of Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of Midazolam: Vz/F.
To evaluate the Vz/F of Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of 1-OH Midazolam: Cmax
To evaluate the Cmax of 1-OH Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of 1-OH Midazolam: AUC0-t
To evaluate the AUC0-t of 1-OH Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of 1-OH Midazolam: AUC0-∞
To evaluate the AUC0-∞ of 1-OH Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of 1-OH Midazolam: Tmax
To evaluate the Tmax of 1-OH Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of 1-OH Midazolam: t1/2z.
To evaluate the t1/2z of 1-OH Midazolam administered alone and in combination with HS-10504
Time frame: 24 hours after administration of Midazolam
Evaluation of PK parameters of HS-10504 and metabolite M6-2: Cmin
To evaluate the Cmin of HS-10504 and metabolite M6-2
Time frame: 24 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: Cmax
To evaluate the Cmax of HS-10504 and metabolite M6-2
Time frame: 24 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: AUC0-24 h
To evaluate the AUC0-24 h of HS-10504 and metabolite M6-2
Time frame: 24 hours after administration of HS-10504
Evaluation of PK parameters of HS-10504 and metabolite M6-2: Tmax.
To evaluate the Tmax of HS-10504 and metabolite M6-2
Time frame: 24 hours after administration of HS-10504
Adverse events
To evaluate the adverse events (AEs) of Midazolam administered alone and in combination with HS-10504.
Time frame: through study completion, an average of 43 days
blood pressure
To evaluate the blood pressure of Midazolam administered alone and in combination with HS-10504.
Time frame: through study completion, an average of 43 days
Pulse
To evaluate the Puls of Midazolam administered alone and in combination with HS-10504.
Time frame: through study completion, an average of 43 days
body temperature
To evaluate the body temperature of Midazolam administered alone and in combination with HS-10504.
Time frame: through study completion, an average of 43 days
respiratory rate
To evaluate the respiratory rate of Midazolam administered alone and in combination with HS-10504.
Time frame: through study completion, an average of 43 days
complete blood count (CBC)
To evaluate the complete blood count (CBC) of Midazolam administered alone and in combination with HS-10504.
Time frame: through study completion, an average of 43 days
urinalysis
To evaluate the urinalysis of Midazolam administered alone and in combination with HS-10504.
Time frame: through study completion, an average of 43 days
blood chemistry
To evaluate the blood chemistry of Midazolam administered alone and in combination with HS-10504.
Time frame: through study completion, an average of 43 days
coagulation tests
To evaluate the coagulation tests of Midazolam administered alone and in combination with HS-10504.
Time frame: through study completion, an average of 43 days
12-lead electrocardiogram(heart rate)
To evaluate the 12-lead electrocardiogram(heart rate) of Midazolam administered alone and in combination with HS-10504
Time frame: through study completion, an average of 43 days
12-lead electrocardiogram(PR)
To evaluate the 12-lead electrocardiogram(PR) of Midazolam administered alone and in combination with HS-10504
Time frame: through study completion, an average of 43 days
12-lead electrocardiogram(RR)
To evaluate the 12-lead electrocardiogram(RR) of Midazolam administered alone and in combination with HS-10504
Time frame: through study completion, an average of 43 days
12-lead electrocardiogram(QRS duration)
To evaluate the 12-lead electrocardiogram(QRS duration) of Midazolam administered alone and in combination with HS-10504
Time frame: through study completion, an average of 43 days
12-lead electrocardiogram(QTcF)
To evaluate the 12-lead electrocardiogram(QTcF) of Midazolam administered alone and in combination with HS-10504
Time frame: through study completion, an average of 43 days
physical examination of Midazolam administered alone and in combination with HS-10504.
To evaluate the abnormal of the physical examination(1) Eyes; 2) Ear, nose, throat; 3) Cardiovascular system; 4) Chest and respiratory system; 5) Abdominal examination; 6) Skin and mucous membranes; 7) Spine and limbs; 8) Musculoskeletal system; 9) Nervous system; 10) Lymph nodes; 11) Genitourinary system; 12) Others.) of Midazolam administered alone and in combination with HS-10504.
Time frame: through study completion, an average of 43 days
No study locations are listed for this record.
Start is estimated for Jun 2026; primary completion for Nov 2026, 4 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangsu Hansoh Pharmaceutical Co., Ltd. →